14
Jul

Sarepta, jockeying with rival BioMarin to commercialize a treatment for Duchenne muscular dystrophy, is looking to buy up complementary assets to fortify its position. But the company’s better-funded competitor believes its long history in rare disease R&D will give it a leg up as the pair move toward make-or-break FDA decisions.

…read more

Source: Sarepta wants to ‘own DMD’ in rare disease race with BioMarin

    

0 No comments